SuperworthPrecipio EPS PRPO
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.68
- Latest quarter, Q2 FY26
- −$0.12
- −340% on a year earlier
- Fiscal year 2025
- −$0.29
Precipio's earnings per share was −$0.68 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.12, down 340% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.29 | n/a |
| FY2024 | −$2.95 | n/a |
| FY2023 | −$4.88 | n/a |
| FY2022 | −$10.60 | n/a |
| FY2021 | −$8.00 | n/a |
| FY2020 | −$25.00 | n/a |
| FY2019 | −$47.00 | n/a |
| FY2018 | −$307.60 | n/a |
| FY2017 | −$5922.00 | n/a |
| FY2016 | −$2937.00 | n/a |
| FY2015 | −$23580.00 | n/a |
| FY2014 | −$17910.00 | n/a |
| FY2013 | −$20700.00 | n/a |
| FY2012 | −$14040.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.12 | −340% | −$0.68 | |
| Q1 FY26 | −$0.81 | n/a | −$0.51 | |
| Q4 FY25 | $0.30 | n/a | −$0.29 | |
| Q3 FY25 | −$0.05 | n/a | −$0.83 | |
| Q2 FY25 | $0.05 | n/a | −$1.20 | |
| Q1 FY25 | −$0.59 | n/a | −$2.08 | |
| Q4 FY24 | −$0.24 | −137% | −$2.95 | |
| Q3 FY24 | −$0.42 | n/a | −$2.06 | |
| Q2 FY24 | −$0.83 | n/a | −$2.68 | |
| Q1 FY24 | −$1.46 | n/a | −$3.73 | |
| Q4 FY23 | $0.65 | n/a | −$4.88 | |
| Q3 FY23 | −$1.04 | n/a | −$7.54 |
Against its peers
Companies in Healthcare nearest Precipio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PRPOPrecipio | −$0.68 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Precipio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.